Lose Pounds, Gain Profits

[View in browser]( [The Spill Logo] BROUGHT TO YOU BY: [Logo]( Proprietary Data Insights Financial Pros’ Top Drug Company Stock Searches in the Last Month Rank Ticker Name Searches #1 [LLY]( Eli Lilly 58 #2 [PFE]( Pfizer 53 #3 [BMY]( Bristol-Myers Squibb 31 #4 [ABBV]( Abbvie 11 #5 [JNJ]( Johnson & Johnson 10 #ad [Unlock Financial Clarity with The Juice]( Brought to you by [Goldco]( [Most Americans are completely unaware of this little known "tax code"]( [Goldco - Most Americans are completely unaware of this little known "tax code"]( Experts warn of a major financial shift. Learn how gold & silver can secure your future before it's too late. [Sign up today.]( Should You Hold Eli Lilly (LLY)? Eli Lilly (LLY) is riding high. Last week, the FDA approved Donanemab, an early-stage treatment for Alzheimer's, one of the first in a vastly underserved community. Current estimates put the drug’s annual revenues between $5-$7 billion annually. Not bad for a company already seeing serious sales growth from its weight loss and diabetes treatment. While it’s the number one drug company stock searched by financial pros according to our TrackStar data, many investors hesitate to jump in at all-time highs. But here’s why you should reconsider. Eli Lilly’s Business Eli Lilly and Company, often simply referred to as Lilly, is a global pharmaceutical powerhouse dedicated to creating medicines that improve people's lives worldwide. With a history spanning over 145 years, Lilly has been at the forefront of groundbreaking discoveries in various therapeutic areas, particularly in diabetes care. The company's portfolio includes innovative medicines in diabetes, oncology, immunology, and neuroscience, as well as a range of animal health products. Lilly's commitment to research and development has created a pipeline of 50 new medicine candidates in clinical development or under regulatory review. [Lilly] [Source: Q1 2024 Earnings Presentation]( The company segments its business into the following areas: - Diabetes and Obesity (62.7% of total revenues) - Includes blockbuster drugs like Mounjaro for type 2 diabetes and Zepbound for obesity. - Oncology (20.6% of total revenues) - Lilly's oncology portfolio features targeted therapies for various types of cancer, such as Verzenio for breast cancer and Cyramza for gastric and lung cancers. - Immunology (9.5% of total revenues) - Key products in this segment include Taltz for psoriasis and psoriatic arthritis and Olumiant for rheumatoid arthritis. - Neuroscience (4.4% of total revenues) - This segment is anchored by Emgality for migraine prevention and Zyprexa for schizophrenia and bipolar disorder. - Other (2.8% of total revenues) - This segment includes various other products, such as Cialis for erectile dysfunction and Forteo for osteoporosis. In Q1 2024, Lilly reported impressive financial results, with revenue jumping 26% year-over-year to $8.77 billion, driven primarily by Mounjaro, Zepbound, Verzenio, and Jardiance. [Q1 2024] [Source: Q1 2024 Earnings Presentation]( Lilly also raised its full-year 2024 revenue guidance by $2 billion, reflecting its confidence in its current portfolio and pipeline. Donanemab approval for Alzheimer's is just one of several drugs with massive potential. Others in the pipeline include Mirikizumab for Crohn's disease and Mirtobrutinib for chronic lymphocytic leukemia. Financials [Financials] Source: Stock Analysis Outside of 2017 and 2022, Eli Lilly’s sales have risen rapidly, with a 5-year average rate of 10.7%. Margins have compressed in recent years as new drugs come online. However, those will improve as production ramps. In the meantime, operating cash flow has halved to $3.7 billion from $7.6 billion in 2021. Capex more than doubled during that same period from $1.3 billion to $3.8 billion. The company issued a small amount of debt to ensure it had enough cash to fund these activities and its $4.2 billion in dividends every year, a paltry 0.6% yield. Current debt stands at $26.3 billion, rather high for the company. We expect that to decline in coming years as cash flows improve, or at least be rolled into lower interest rates. Valuation [Valuation] Source: Seeking Alpha Eli Lilly’s valuation isn’t on the same planet as its peers. Company’s like Pfizer (PFE) are reeling from the plunge in Covid demand while Bristol Myers Squibb (BMY) faces a patent clifff. The assumption is Eli Lilly will grow into its multiples as margins expand on higher sales. Growth [Growth] Source: Seeking Alpha None of Lilly’s peers match its revenue growth. Every other company on this list saw and is forecasting flat or negative growth, while Lilly expects +20% sales in 2024. This disparity accounts for the valuation gap between companies. Profitability [Profit] Source: Seeking Alpha Don’t let the high cash flow margins for the other companies fool you. That happens when drugs are mature. Cash flows will dwindle as sales do when drugs go generic. That’s why drug companies need growth to survive. [Biggest Prediction of My 50-Year Career on Wall Street]( Today, I'm going public with something I've never said on national air... not in any of my appearances on Fox Business or CNBC. I'm a little nervous about it... But I stand behind the big prediction I'm making right now... because I've never been more confident that a strange day I foresee coming to America could make you a great deal of money. Today, my newest prediction is even bigger. In fact, I'm going one step further. I'm giving away the ticker symbol of the #1 stock to buy now... using the same system that bears my name on every Bloomberg terminal on Wall Street. [Click here to learn the full details.]([Ad] Our Opinion 8/10 It’s hard not to get behind Eli Lilly and its future. Despite the stock hitting fresh all-time highs, the number of growth products coming to market and already underway put Lilly at the top of many categories. We see a lot of room for the stock to keep pushing higher even from these prices. [-facebook-share]( [-twitter-share]( [-linkedin-share]( [-email-share](mailto:?body= https%3A%2F%2Finvestingchannel.com%2F%3Fp%3D619187?utm_medium=ic-nl&utm_source=119841 ) News & Insights Just Spilled - [Looking to Invest in Bitcoin? Try These 5 ETFs]( - [Adding Color to the Investment Spectrum]( - [Pros Pick Their Top 5 Cybersecurity Stock]( - [Can Advanced Micro Devices (AMD) Beat Nvidia (NVDA)?]( [News & Insights-facebook-share]( [News & Insights-twitter-share]( [News & Insights-linkedin-share]( [News & Insights-email-share](mailto:?body= https%3A%2F%2Finvestingchannel.com%2F%3Fp%3D619187?utm_medium=ic-nl&utm_source=119841 ) [We want to hear from you. Let us know your thoughts by clicking here]( [Ads] [InvestingChannel Logo](#) Follow us on: [Facebook Logo]( [LinkedIn Logo]( [Twitter Logo]( [Instagram Logo]( To ensure delivery of all emails, [allow us on your list](. Manage your subscriptions with our [preference center](. [Unsubscribe here.]( View our privacy policy [here](. Copyright ©2024 InvestingChannel. All rights reserved. 1325 Avenue of the Americas, Floor 27 & 28 New York, New York 10019 Disclaimer: This is not investment advice. This InvestingChannel, Inc., newsletter is for information purposes only and is based on opinion. Futures, forex, stock, and options trading are not appropriate for all investors. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or methodology has ever been developed that can ensure returns or eliminate losses. InvestingChannel, Inc., makes no representation or implication that using any of the methodologies or systems in this newsletter will generate returns or insure against losses. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions. [Link](